Venture capital is hopping, attracted to some of the past several years’ successes.
Venture capital is hopping, attracted to some of the past several years’ successes. Recently launched LifeMine Therapeutics is a big-concept company, looking to combine genomics, artificial intelligence, and synthetic biology to mimic some of nature’s biological wizardry. Kaleido is also working around another current buzzword, the microbiome. Disarm Therapeutics is looking to prevent axonal degeneration in neurologic disease. And Gritstone, while not quite as new as these other companies, is going after personalized cancer immunotherapies. The money is flowing, so grab it while you can! -KT
